Immune Cell-Targeted Delivery Carrier for In Vivo Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapy methods are complex, costly, and uncomfortable for patients due to the need for in vitro cell modification and prolonged venous access for autologous cell collection.
Innovation Solution
A modified delivery carrier comprising a delivery carrier and a targeting domain that can load agents and specifically target immune cell surface antigens, eliminating the need for in vitro cell modification and autologous cell collection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cell therapy methods are used involving in vitro cell modification and autologous cell collection, then therapeutic effect is achieved, but operational complexity increases and patient comfort deteriorates
Solution Approach 1:
The patent extracts the cell collection and in vitro modification steps from the traditional cell therapy process. Instead of collecting autologous cells and modifying them in vitro, the invention delivers modification agents directly in vivo through a targeted delivery system, eliminating the complex ex vivo manipulation steps while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces a delivery carrier as an intermediary between the modification agent and the target cells. This carrier facilitates in vivo delivery by protecting the agent, enabling targeted delivery to specific cell types, and allowing controlled release, thereby simplifying the overall process compared to direct in vitro manipulation.
2Reliability
If traditional cell therapy methods are used involving in vitro cell modification and autologous cell collection, then therapeutic effect is achieved, but treatment cost increases
Solution Approach 1:
By removing the need for expensive GMP-grade cell culture facilities, specialized equipment for in vitro manipulation, and extensive quality control processes for cell processing, the invention significantly reduces infrastructure and operational costs while maintaining therapeutic outcomes through in vivo delivery.
Solution Approach 2:
The body's own physiological environment serves as the reaction vessel for cell modification, eliminating the need for expensive external bioreactors and culture systems. The in vivo delivery system leverages the body's natural processes to achieve cell modification, reducing manufacturing costs.
3Quantity of substance
If traditional cell therapy methods are used involving prolonged venous access for autologous cell collection, then sufficient cells are obtained, but patient comfort deteriorates
Solution Approach 1:
The invention segments the cell modification process into two independent components: (1) delivery of modification agents via minimally invasive routes (eliminating prolonged venous access), and (2) natural in vivo uptake by target cells. This allows sufficient cell quantity to be achieved without compromising patient comfort during the delivery phase.
Solution Approach 2:
The delivery carrier acts as an intermediary that transports modification agents to target cells without requiring direct access to large volumes of blood or prolonged venous catheterization. This enables sufficient cellular modification through targeted delivery rather than bulk cell collection.
Data Source
Figure 1~3
Figure 4A~5A
Figure 5B
AI summary
The present invention relates to a modified delivery carrier and use thereof. The modified delivery carrier comprises a delivery carrier and a targeting domain coupled to the delivery carrier, wherein the delivery carrier is used for loading an agent, and the targeting domain is capable of specifically targeting a surface antigen of an immune cell.